Psoriasis is a chronic, immune-mediated skin condition. It causes red, scaly, itchy, often inflamed patches. Because the ...

Sun Pharma launches Ilumya (Tildrakizumab) in India, expanding its specialty medicines portfolio and bringing advanced ...

Innovent's Pecondle, a recombinant anti-interleukin-23p19 subunit, receives China NMPA approval to treat moderate-to-severe plaque psoriasis: San Francisco Monday, December 1, 202 ...

Sun Pharma's managing director, Kirti Ganorkar, said Ilumya is already available in 35 countries and has consistently ...

Sun Pharmaceutical Industries on Monday said it has launched its global innovative drug ILUMYA in India for the treatment of ...

Researchers in China report that global incidence rates of psoriasis rose slightly from 1990 to 2021 and are projected to ...

Sun Pharma introduces ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis treatment. A novel biologic with proven efficacy.

North America and Western Europe — two wealthier regions of the world — reported the highest incidences and are projected to ...

“Our study demonstrated in a large real-world population that long-term treatment of up to 5 years with adalimumab in adult patients with psoriasis led to a sustained improvement in the practice of ...

Despite challenges such as high costs and access barriers, the demand for effective, tailored therapies continues to rise, transforming the psoriasis treatment landscapeDublin, Nov. 26, 2025 (GLOBE ...

An expert panel calls the requirement for tuberculosis testing before prescribing IL-17 and IL-23 biologics for psoriasis an ...